Practitioner's Docket No. MPI00-079P1RCP2CN1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Meyers, Rachel E., et al
Application No.: 10/664,506 Group No.: 1652
Filed: September 17, 2003 Examiner: N/A
For: 32142, 21481, 25964, 21686, NOVEL HUMAN DEHYDROGENASE
MOLECULES AND USES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

Note: The PTO will not correct the filing receipt until the application is complete (in other words, the applicant files a response to the notice to file missing parts).

2. There is an error with respect to the following data, which is:

[X] incorrectly entered

[] omitted.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING


- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.



Signature

Date: January 16, 2004

Diana Gentile
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-079P1RCP2CN1M

<i>Error in</i>	<i>Correct data</i>
1. <input type="checkbox"/> Applicant's name	1.
2. <input checked="" type="checkbox"/> Applicant's address	2. William James Cook, <u>Hanover</u> , NH Laura A. Rudolph-Owen, <u>Medford</u> , MA
3. <input type="checkbox"/> Title	3.
4. <input type="checkbox"/> Filing Date	4.
5. <input type="checkbox"/> Serial Number	5.
6. <input type="checkbox"/> Foreign/PCT Application Re:	6.
7. <input type="checkbox"/> Other	7.

3. *(complete the following applicable item)*

A. ☐ The correction(s) is/are not due to any error by applicant and no fee is due.

OR

B. ☒ At least one of the above corrections is due to applicant's error and the fee therefor, under 37 C.F.R. Section 1.19(h), of \$25.00 is paid as follows:

☐ Enclosed is check for \$25.00.

☒ Charge Account 501668 the sum of \$25.00.

A duplicate of this request is enclosed.

January 16, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By 
Kerri Pollard Schray
Registration No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/664,506	09/17/2003	1652	2566	MPI00-079P1RCP2CN1M	43	42	8

30405
 MILLENNIUM PHARMACEUTICALS, INC.
 75 SIDNEY STREET
 CAMBRIDGE, MA 02139



CONFIRMATION NO. 6793

FILING RECEIPT



OC000000011306463

Date Mailed: 11/19/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Rachel Meyers, Newton, MA; ✓ *Manave*
 William James Cook, New London, NH; ✓ *medford*
 Mark Williamson, Saugus, MA; ✓
 Laura A. Rudolph-Owen, Jamaica Plain, MA; ✓
 Ruth Gimeno, Wellesley, MA; ✓

Assignment For Published Patent Application

Millennium Pharmaceuticals;

Domestic Priority data as claimed by applicant

This application is a CON of 09/838,561 04/18/2001 PAT 6,627,423
 which is a CIP of 09/816,760 03/23/2001 PAT 6,613,555
 which is a CIP of 09/634,955 08/08/2000 PAT 6,511,834
 which claims benefit of 60/192,002 03/24/2000

Foreign Applications

If Required, Foreign Filing License Granted: 11/18/2003

Projected Publication Date: To Be Determined - pending completion of Omitted Items

Non-Publication Request: No

Early Publication Request: No

Title

32142, 21481, 25964, 21686, novel dehydrogenase molecules and uses therefor

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).